Analysts at StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) in a research report issued to clients and investors on Thursday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Aptevo Therapeutics Stock Performance
Shares of NASDAQ:APVO opened at $0.41 on Thursday. Aptevo Therapeutics has a 12-month low of $0.28 and a 12-month high of $48.40. The business has a 50 day moving average of $0.56 and a 200-day moving average of $3.08.
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last released its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($9.95) earnings per share for the quarter, topping the consensus estimate of ($14.10) by $4.15. As a group, analysts expect that Aptevo Therapeutics will post -8.86 EPS for the current year.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Read More
- Five stocks we like better than Aptevo Therapeutics
- Buy P&G Now, Before It Sets A New All-Time High
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Best Stocks Under $10.00
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
